Research Analysts Set Expectations for BioCardia Q1 Earnings

BioCardia, Inc. (NASDAQ:BCDA) – Research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for BioCardia in a research note issued on Thursday, March 26th. HC Wainwright analyst J. Pantginis expects that the company will post earnings of ($0.17) per share for the quarter. The consensus estimate for BioCardia’s current full-year earnings is ($3.52) per share. HC Wainwright also issued estimates for BioCardia’s Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.17) EPS and Q4 2026 earnings at ($0.18) EPS.

BioCardia (NASDAQ:BCDA) last posted its quarterly earnings data on Tuesday, March 24th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.14.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of BioCardia in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $25.00.

BioCardia Price Performance

Shares of BioCardia stock opened at $1.18 on Friday. The firm’s fifty day simple moving average is $1.24 and its 200-day simple moving average is $1.35. BioCardia has a 12 month low of $1.00 and a 12 month high of $3.20. The stock has a market capitalization of $12.52 million, a price-to-earnings ratio of -0.91 and a beta of 0.60.

Institutional Trading of BioCardia

A number of hedge funds have recently added to or reduced their stakes in BCDA. DRW Securities LLC acquired a new stake in BioCardia during the 4th quarter worth approximately $72,000. Geode Capital Management LLC increased its holdings in shares of BioCardia by 70.4% in the fourth quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock valued at $83,000 after purchasing an additional 27,263 shares during the period. Finally, Cetera Investment Advisers purchased a new stake in shares of BioCardia during the second quarter worth approximately $40,000. 20.57% of the stock is owned by institutional investors and hedge funds.

About BioCardia

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.